mHSPC
Metastatic hormone-sensitive prostate cancer
Advertisement
The phase II UpFrontPSMA study evaluated the use of [177Lu]Lu-PSMA-617 administered before docetaxel.
Dr. Greenstein shares insights on the overall survival benefit of apalutamide over enzalutamide in a recent real-world study.
At ESMO 2024, experts discuss androgen-deprivation therapy in HSPC as well as the ARANOTE trial.
Experts discuss mHSPC discuss risk stratification, developed novel approaches for treatment, and treatment sequencing.
Phase III mHSPC trials can take up to a decade to complete when OS is used as the primary endpoint.
The PNI is commonly used as a prognostic factor for malignant tumors, but its potential use for prostate cancer is unknown.
Patients with a suboptimal PSA response who are administered intensified ADT often experience worse survival outcomes.
A meta-analysis sought to determine the efficacy of systemic therapies in patients with PCa and poor performance status.
Updated AUA/SUO Guideline on Advanced Prostate Cancer Offers New Recommendations on Imaging, Testing
The updated guideline emphasizes the use of PSMA PET for periodic staging, as well as the use of ADT.
Results from the CHAARTED trial demonstrated that ADT and docetaxel improves OS and QOL at 12 months compared with ADT alone.
Researchers studied several trials including LATITUDE and STAMPEDE to find similar characteristics among ARAT treatments.
The STAMPEDE trial examined the addition of zoledronic acid, docetaxel, or both to ADT for the treatment of mHSPC.
Several physicians highlight the newest data on radiation for metastatic prostate cancer and its role moving forward.
New research has reported updates on the primary OS analysis of the ENZAMET trial to define the benefit of enzalutamide.
A recent study examined safety and efficacy from the ARASENS trial for certain subgroups by disease volume and risk.
Is it possible to avoid or delay systemic therapy for patients with oligometastatic prostate cancer? A new study suggests so.
An analysis highlighted real-world treatment of patients with mHSPC in the community who received at least 1 line of therapy.
Tanya Dorff, MD, shares the barriers to utilizing PARP inhibitors plus AR-targeted agents in early prostate cancer settings.
Dr. Deek shares what research should be done to better personalize care for patients with oligometastatic prostate cancer.
Dr. Deek shares what “high-risk mutation” signified in his study and how patients with “high-risk mutation” should be ...
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.